Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.60
AMEX:PLX's Cash-to-Debt is ranked lower than
90% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AMEX:PLX: 0.60 )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:PLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: 0.6
Equity-to-Asset -0.35
AMEX:PLX's Equity-to-Asset is ranked lower than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMEX:PLX: -0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:PLX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.12 Max: 0.8
Current: -0.35
-1.15
0.8
Debt-to-Equity -2.80
AMEX:PLX's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. AMEX:PLX: -2.80 )
Ranked among companies with meaningful Debt-to-Equity only.
AMEX:PLX' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.07  Med: -1.01 Max: 27.25
Current: -2.8
-9.07
27.25
Piotroski F-Score: 3
Altman Z-Score: -7.99
Beneish M-Score: -0.31
WACC vs ROIC
12.15%
-686.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -203.39
AMEX:PLX's Operating Margin % is ranked lower than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AMEX:PLX: -203.39 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:PLX' s Operating Margin % Range Over the Past 10 Years
Min: -8239.43  Med: -542.39 Max: -35.36
Current: -203.39
-8239.43
-35.36
Net Margin % -428.88
AMEX:PLX's Net Margin % is ranked lower than
74% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. AMEX:PLX: -428.88 )
Ranked among companies with meaningful Net Margin % only.
AMEX:PLX' s Net Margin % Range Over the Past 10 Years
Min: -8103.09  Med: -436.59 Max: 1329.9
Current: -428.88
-8103.09
1329.9
ROA % -94.65
AMEX:PLX's ROA % is ranked lower than
86% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AMEX:PLX: -94.65 )
Ranked among companies with meaningful ROA % only.
AMEX:PLX' s ROA % Range Over the Past 10 Years
Min: -94.65  Med: -34.11 Max: 66.1
Current: -94.65
-94.65
66.1
ROC (Joel Greenblatt) % -600.06
AMEX:PLX's ROC (Joel Greenblatt) % is ranked lower than
58% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AMEX:PLX: -600.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:PLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -988.83  Med: -224.15 Max: -67
Current: -600.06
-988.83
-67
3-Year EBITDA Growth Rate -20.60
AMEX:PLX's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AMEX:PLX: -20.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:PLX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: -11.95 Max: 83
Current: -20.6
-53.3
83
3-Year EPS without NRI Growth Rate -8.60
AMEX:PLX's 3-Year EPS without NRI Growth Rate is ranked lower than
59% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AMEX:PLX: -8.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMEX:PLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -49.3  Med: -7.2 Max: 54.6
Current: -8.6
-49.3
54.6
GuruFocus has detected 2 Warning Signs with Protalix BioTherapeutics Inc $AMEX:PLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:PLX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PLX Guru Trades in Q3 2016

Jim Simons 180,900 sh (+75.80%)
» More
Q4 2016

PLX Guru Trades in Q4 2016

Jim Simons 479,300 sh (+164.95%)
» More
Q1 2017

PLX Guru Trades in Q1 2017

Jim Simons 1,927,500 sh (+302.15%)
» More
Q2 2017

PLX Guru Trades in Q2 2017

Jim Simons 2,300,800 sh (+19.37%)
» More
» Details

Insider Trades

Latest Guru Trades with AMEX:PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:GLMD, NAS:BLRX, XTAE:EVGN, XTAE:APOP, OTCPK:TOMDF, XTAE:CBI, NAS:ORMP, NAS:PSTI, XTAE:BVXV, NAS:MDWD, NAS:ADHD, XTAE:CFBI, NAS:VBLT, XTAE:TRPX, XTAE:RDHL, XTAE:KTOV, XTAE:XTL, XTAE:CLPT, NAS:ORPN, OTCPK:TIKRF » details
Traded in other countries:PBD.Germany, PLX.Israel,
Headquarter Location:Israel
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Protalix BioTherapeutics Inc was originally incorporated in the State of Florida in April 1992. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. Using its ProCellEx system, it is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Its initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company has developed ElelysoTM, its first drug product, ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The Company is now also applying the properties of its ProCellEx system for the oral delivery of therapeutic proteins. The Company relies on a single approved supplier for certain materials relating to the current expression of its proprietary biotherapeutic proteins through ProCellEx. It faces competition from companies with approved treatments of Gaucher disease. Some such companies include iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH. The Company has 94 pending patent applications and one joint pending patent application with a third party. The Company is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.

Top Ranked Articles about Protalix BioTherapeutics Inc

Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Protalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update Conference Call on August 9, 2017
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference
Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility
Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference
Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
Protalix BioTherapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on May 10, 2017

Ratios

vs
industry
vs
history
PS Ratio 4.80
PLX's PS Ratio is ranked higher than
60% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. PLX: 4.80 )
Ranked among companies with meaningful PS Ratio only.
PLX' s PS Ratio Range Over the Past 10 Years
Min: 3.26  Med: 41.89 Max: 1618
Current: 4.8
3.26
1618
EV-to-EBIT -1.88
PLX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. PLX: -1.88 )
Ranked among companies with meaningful EV-to-EBIT only.
PLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -51  Med: -11.8 Max: -1.85
Current: -1.88
-51
-1.85
EV-to-EBITDA -1.94
PLX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. PLX: -1.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
PLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -81.6  Med: -12.9 Max: -1.92
Current: -1.94
-81.6
-1.92
EV-to-Revenue 6.39
PLX's EV-to-Revenue is ranked lower than
55% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. PLX: 6.39 )
Ranked among companies with meaningful EV-to-Revenue only.
PLX' s EV-to-Revenue Range Over the Past 10 Years
Min: 5  Med: 40.5 Max: 1439
Current: 6.39
5
1439
Current Ratio 2.56
PLX's Current Ratio is ranked lower than
60% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. PLX: 2.56 )
Ranked among companies with meaningful Current Ratio only.
PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 5 Max: 91.65
Current: 2.56
1.02
91.65
Quick Ratio 2.19
PLX's Quick Ratio is ranked lower than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. PLX: 2.19 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5 Max: 91.65
Current: 2.19
0.96
91.65
Days Inventory 160.32
PLX's Days Inventory is ranked lower than
72% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. PLX: 160.32 )
Ranked among companies with meaningful Days Inventory only.
PLX' s Days Inventory Range Over the Past 10 Years
Min: 24.15  Med: 207.5 Max: 3304.7
Current: 160.32
24.15
3304.7
Days Sales Outstanding 68.56
PLX's Days Sales Outstanding is ranked lower than
64% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. PLX: 68.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
PLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.95  Med: 168.97 Max: 2016.91
Current: 68.56
14.95
2016.91
Days Payable 207.51
PLX's Days Payable is ranked higher than
85% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. PLX: 207.51 )
Ranked among companies with meaningful Days Payable only.
PLX' s Days Payable Range Over the Past 10 Years
Min: 174.16  Med: 731.34 Max: 2222.44
Current: 207.51
174.16
2222.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.80
PLX's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. PLX: -9.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -539.3  Med: -5 Max: 14
Current: -9.8
-539.3
14

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.11
PLX's Price-to-Median-PS-Value is ranked higher than
93% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. PLX: 0.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.6 Max: 31.52
Current: 0.11
0.01
31.52
Earnings Yield (Greenblatt) % -53.31
PLX's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. PLX: -53.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -54.02  Med: -8.5 Max: -2
Current: -53.31
-54.02
-2

More Statistics

Revenue (TTM) (Mil) $16.00
EPS (TTM) $ -0.63
Beta1.37
Short Percentage of Float5.54%
52-Week Range $0.26 - 1.51
Shares Outstanding (Mil)133.36

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 27 48
EPS ($) -0.52 -0.17
EPS without NRI ($) -0.52 -0.17
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PLX

Headlines

Articles On GuruFocus.com
Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Sep 05 2017 
Protalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update Conferen Jul 31 2017 
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 Jul 25 2017 
Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fib Jun 07 2017 
Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Produc Jun 01 2017 
Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference May 25 2017 
Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase al May 23 2017 
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update May 10 2017 
Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study o May 09 2017 
Protalix BioTherapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conferenc May 01 2017 

More From Other Websites
Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global... Sep 05 2017
Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Aug 25 2017
Edited Transcript of PLX earnings conference call or presentation 9-Aug-17 12:30pm GMT Aug 10 2017
Protalix posts 2Q profit Aug 09 2017
Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update Aug 09 2017
Investor Network: Protalix BioTherapeutics, Inc. to Host Earnings Call Aug 09 2017
Protalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update... Jul 31 2017
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018... Jul 25 2017
Are Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock? May 30 2017
Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Edited Transcript of PLX earnings conference call or presentation 10-May-17 12:30pm GMT May 11 2017
Protalix reports 1Q loss May 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}